Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressants Improving Cognitive Symptoms in Alzheimer's Disease with Comorbid Depression
ChiCTR2200057190Phase 4Not yet recruiting
- Sponsor
- Affiliated Kangning Hospital of Ningbo University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sertraline, paroxetine and duloxetine in Alzheimer's disease (AD), major depressive disorder (MDD) and anxiety disorder (4 arms), sponsored by Affiliated Kangning Hospital of Ningbo University. Primary endpoints: Psychological scales score, Near-infrared imaging (resting-state, language task, working memory task) and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
sertralineparoxetineduloxetine
03
Conditions
Alzheimer's disease (AD)major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2200057190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057190.